Use of Laghu Talisadi Churna and Salbutamol in management of Bronchial Asthma.

Randomised comparative clinical controlled assessment of Laghu Talisadi Churna and Salbutamol in management of tamak shwas. - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/03/063781

Enrollment

Registered

2024-03-07

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J459- Other and unspecified asthma

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients of any gender Age 18 to 70 years Recently diagnosed case of Bronchial Asthma FEV1 35 to 79%

Exclusion criteria

Exclusion criteria: K/C/O -Chronic obstructive pulmonary disease. K/C/O - Infective pulmonary pathology. Any systemic disorder i.e. K/C/O renal & Cardiac disorders. K/C/O- immuno-compromised disease K/C/O- Malignancy disease K/C/O-Chornic Interstitial Lung Disease Pregnant and lactating women k/C/O-Diabetes mellitus

Design outcomes

Primary

Measure	Time frame
•To assess the symptomatic relief . •To find out the effect of Laghu Talisadi Churna on FEV1 Timepoint: Assessment on 0th 7th 14th 21th 28th days.	—

Secondary

Measure	Time frame
•To observe any association between Tamak Shwas and raised IgE levels? And If there is association, it is a study showing that the study drug lowers IgE levels. Timepoint: Assessment on 0th 7th 14th 21th 28th days.	—

Countries

India

Contacts

Public ContactDr Avadhut Vitthal Khabale

Dr. G. D.Pol Foundation, YMT Ayurvedic Medical College.

drminalsvaidya@gmail.com9323790371

Outcome results